Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.
Study Type
OBSERVATIONAL
Enrollment
80
Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
180 Fenglin Road
Shanghai, Shanghai Municipality, China
History of variceal bleeding
Have a history of the occurrence of gastroesophageal variceal bleeding
Time frame: 1 day (the same time as diagnosis)
1-year death rate
1-year death rate
Time frame: 1 year
Complications of portal hypertension
The concurrence of complications of portal hypertension (ascites, infections, variceal bleeding, et al)
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.